DAVENPORT & Co LLC Has $117.68 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

DAVENPORT & Co LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 61.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,695,522 shares of the company's stock after purchasing an additional 642,810 shares during the quarter. DAVENPORT & Co LLC's holdings in Novo Nordisk A/S were worth $117,682,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Impact Investors Inc grew its position in Novo Nordisk A/S by 14.1% during the first quarter. Impact Investors Inc now owns 5,698 shares of the company's stock worth $396,000 after buying an additional 704 shares in the last quarter. Mather Group LLC. lifted its position in shares of Novo Nordisk A/S by 6.2% during the 1st quarter. Mather Group LLC. now owns 5,933 shares of the company's stock valued at $412,000 after acquiring an additional 345 shares during the period. Koshinski Asset Management Inc. grew its holdings in shares of Novo Nordisk A/S by 27.1% during the 1st quarter. Koshinski Asset Management Inc. now owns 15,570 shares of the company's stock worth $1,081,000 after purchasing an additional 3,316 shares in the last quarter. Washington Trust Advisors Inc. increased its position in shares of Novo Nordisk A/S by 50.2% in the first quarter. Washington Trust Advisors Inc. now owns 778 shares of the company's stock worth $54,000 after purchasing an additional 260 shares during the period. Finally, Mmbg Investment Advisors CO. raised its stake in Novo Nordisk A/S by 69.7% in the first quarter. Mmbg Investment Advisors CO. now owns 29,985 shares of the company's stock valued at $2,116,000 after purchasing an additional 12,320 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on NVO shares. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Finally, Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded up $0.83 during midday trading on Tuesday, reaching $69.85. 6,841,960 shares of the company were exchanged, compared to its average volume of 7,239,563. The stock's 50-day moving average price is $69.32 and its 200-day moving average price is $76.55. The stock has a market cap of $311.88 billion, a P/E ratio of 20.67, a PEG ratio of 1.22 and a beta of 0.66. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $145.99.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.